Cancer Care's AIDS Pain Booklet Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

NEW YORK--Cancer Care, Inc. has a new booklet, "Pain in HIV/AIDS: Control Your Pain So It Doesn't Control You," that provides information about pain management to people with HIV, to help them advocate for themselves and receive

NEW YORK--Cancer Care, Inc. has a new booklet, "Pain in HIV/AIDS:Control Your Pain So It Doesn't Control You," that provides informationabout pain management to people with HIV, to help them advocate for themselvesand receive effective pain management. For free copies, call Cancer Careat 212-221-3300 or toll-free at 1-800-813-4673.

Articles in this issue
New Board to Deal With Cancer Policy Issues
MoAb Shows Positive Results in Lymphoma Patients
Prostate Cancer Gene Location Narrowed to Chromosome 1 Arm
New BCG Bladder Cancer Indication Gets Panel Nod
Panel Advises FDA To OK Letrozole for Advanced Breast Cancer
Limited Diagnostic Testing After Breast Cancer Treatment Urged
Pressures of Managed Care Spur Interest in Clinical Guidelines
Baltimore Will Head New Effort To Develop a Vaccine for HIV
Epidemiologist Challenges Tamoxifen, Second Cancer Link
Cancer Care's AIDS Pain Booklet Available
AIDS Center Director Offers Advice on Selecting a Physician
Good Outcomes Seen With Hyperfractionated Conformal RT
Goals of Planned National Pain Research Consortium Outlined
New Evidence Supports Screening in Younger Women
Interferon Improves Survival in CML
Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content
Patients receiving neoadjuvant chemotherapy plus radical nephroureterectomy for upper tract urothelial carcinoma appear more likely to experience nodal downstaging.

Chemo/Nephroureterectomy Increases pCR Likelihood in Urothelial Carcinoma

December 2nd 2023
Article

Patients receiving neoadjuvant chemotherapy plus radical nephroureterectomy for upper tract urothelial carcinoma appear more likely to experience nodal downstaging.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.

Data Show Barriers to Immunotherapy Access in Clear Cell RCC Population

December 1st 2023
Article

Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.

New treatment updates could help find more patient subtypes to target and treat in the world of CRC.

Multidisciplinary Care and New Treatment Options in CRC

November 20th 2023
Podcast

New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.

More than half of the patients with non–muscle-invasive bladder cancer in the BOND-003 trial achieve a complete response at 6 months following treatment with cretostimogene grenadenorepvec.

Cretostimogene Grenadenorepvec Yields Durable Responses in NMIBC

December 1st 2023
Article

More than half of the patients with non–muscle-invasive bladder cancer in the BOND-003 trial achieve a complete response at 6 months following treatment with cretostimogene grenadenorepvec.

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

CAR T-cell Therapy Remains Preferred Options for Relapsed/Refractory Multiple Myeloma

December 1st 2023
Article

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.